Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Sector Analysis

Biological Products, (No Diagnostic Substances)

Standard Industrial Classification: SIC 2836

Industry Insider Sentiment Analysis

The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.

Filing Date Trade Date Ticker Company Reporting Person Relationship Type Price Qty Total, $ Owned After
2026-08-04 20:50 2026-07-31 ACOG Alpha Cognition Inc. Opaleye Management Inc. 10% owner BUY $8.00 52,900 $422,978 3,048,223
2026-08-03 22:26 2026-07-30 ADPT Adaptive Biotechnologies Corp BOBULSKY SUSAN Officer SELL $24.00 1,299 $31,176 399,989
2026-07-31 21:13 2026-07-29 ARTV Artiva Biotherapeutics, Inc. RA CAPITAL MANAGEMENT, L.P. Director, 10% owner BUY $9.96 45,768 $455,726 17,329,570
2026-07-31 20:15 2026-07-29 DBVT DBV Technologies S.A. Mohideen Pharis Officer SELL $2.70 464 $1,253 144,531
2026-07-31 20:15 2026-07-29 MAZE Maze Therapeutics, Inc. Dandekar Atul Officer OPT+S $27.34 7,500 $205,031 26,250
2026-07-31 20:05 2026-07-30 VCEL Vericel Corp SIEGAL JONATHAN Officer OPT+S $48.90 4,500 $220,050 1,078
2026-07-30 21:29 2026-07-28 NBIX NEUROCRINE BIOSCIENCES INC Norwalk Leslie V Director OPT+S $182.01 1,250 $227,508 1,588
2026-07-30 20:12 2026-07-28 RLAY Relay Therapeutics, Inc. Bergstrom Donald A Officer SELL $18.61 2,237 $41,631 407,660
2026-07-30 20:13 2026-07-28 RLAY Relay Therapeutics, Inc. Rahmer Peter Officer SELL $18.61 748 $13,920 228,165
2026-07-30 20:13 2026-07-28 RLAY Relay Therapeutics, Inc. Catinazzo Thomas Officer SELL $18.61 1,459 $27,152 158,285
2026-07-30 01:05 2026-07-29 BCDA BioCardia, Inc. Altman Peter Director, Officer BUY $0.78 5,000 $3,900 373,885
2026-07-29 23:09 2026-07-27 SCTX Scribe Therapeutics, Inc. AH Bio Fund II, L.P. 10% owner BUY $15.00 333,333 $4,999,995 2,385,075
2026-07-29 22:47 2026-07-27 SCTX Scribe Therapeutics, Inc. ORBIMED ADVISORS LLC Director BUY $15.00 1,000,000 $15,000,000 1,348,825
2026-07-29 22:50 2026-07-27 SCTX Scribe Therapeutics, Inc. GORDON CARL L Director BUY $15.00 1,000,000 $15,000,000 1,348,825
2026-07-29 20:51 2026-07-28 EDIT Editas Medicine, Inc. Burkly Linda Officer SELL $2.67 4,928 $13,158 62,369
2026-07-29 20:05 2026-07-27 BEAM Beam Therapeutics Inc. Simon Amy Officer SELL $25.74 16,667 $429,037 85,696
2026-07-29 19:19 2026-07-29 OTLK Outlook Therapeutics, Inc. Sukhtian Faisal Ghiath Director BUY $1.05 95,398 $99,996 220,972
2026-07-29 01:30 2026-07-24 SCTX Scribe Therapeutics, Inc. Aghazadeh Behzad Director, 10% owner BUY $15.16 2,391,238 $36,259,777 3,088,888
2026-07-28 21:24 2026-07-24 ARTV Artiva Biotherapeutics, Inc. RA CAPITAL MANAGEMENT, L.P. Director, 10% owner BUY $9.99 41,319 $412,777 17,283,802
2026-07-28 20:05 2026-07-24 ACOG Alpha Cognition Inc. Opaleye Management Inc. 10% owner BUY $7.90 130 $1,027 2,995,323
2026-07-28 20:10 2026-07-27 PCVX Vaxcyte, Inc. PICKERING GRANT Director, Officer OPT+S $55.63 18,198 $1,012,375 133,215
2026-07-28 01:42 2026-07-23 SCTX Scribe Therapeutics, Inc. Lucas Svetlana Officer BUY $15.00 3,000 $45,000 3,000
2026-07-28 01:20 2026-07-23 SCTX Scribe Therapeutics, Inc. Parrot David Officer BUY $15.00 2,666 $39,990 1,333
2026-07-27 20:05 2026-07-23 TWST Twist Bioscience Corp Finn Patrick John Officer SELL $93.89 2,238 $210,133 272,566
2026-07-25 01:00 2026-07-22 SRZN Surrozen, Inc./DE TCG Crossover GP II, LLC 10% owner SELL $21.25 325,000 $6,906,250 574,047
2026-07-24 21:59 2026-07-24 IMVT Immunovant, Inc. Pande Atul Director OPT+S $39.80 1,500 $59,700 116,731
2026-07-24 21:57 2026-07-23 IMVT Immunovant, Inc. Stout Jay S Officer SELL $38.69 2,857 $110,537 205,341
2026-07-24 21:57 2026-07-23 IMVT Immunovant, Inc. Girao Tiago Officer SELL $38.69 6,798 $263,015 240,798
2026-07-24 21:11 2026-07-22 DYAI DYADIC INTERNATIONAL INC Francisco Trust under agreement dated February 28, 1996 10% owner SELL $1.31 95,392 $124,954 3,280,272
2026-07-24 20:05 2026-07-22 ACOG Alpha Cognition Inc. Opaleye Management Inc. 10% owner BUY $7.82 200,086 $1,565,493 2,995,193
2026-07-24 01:21 2026-07-13 ARTV Artiva Biotherapeutics, Inc. RA CAPITAL MANAGEMENT, L.P. Director, 10% owner BUY $8.94 6,522 $58,307 16,817,543
2026-07-24 01:22 2026-07-21 ARTV Artiva Biotherapeutics, Inc. RA CAPITAL MANAGEMENT, L.P. Director, 10% owner BUY $9.76 264,586 $2,583,312 17,242,483
2026-07-23 23:34 2026-07-21 ADPT Adaptive Biotechnologies Corp ROBINS HARLAN S Officer OPT+S $21.89 492,400 $10,780,409 812,058
2026-07-23 13:34 2026-07-22 GRML Greenland Mines Ltd Sawyer Jason David Director BUY $0.23 240,000 $55,944 240,000
2026-07-22 01:12 2026-07-21 MGTX MeiraGTx Holdings plc Giroux Richard Officer SELL $12.51 56,000 $700,560 908,530
2026-07-21 20:54 2026-07-16 VOR Vor Biopharma Inc. RA CAPITAL MANAGEMENT, L.P. 10% owner SELL $19.75 213 $4,207 4,501,882
2026-07-21 01:47 2026-07-16 IMA ImageneBio, Inc. Lally Robert B Officer SELL $5.42 3,196 $17,334 55,582
2026-07-20 23:19 2026-07-16 ADPT Adaptive Biotechnologies Corp BOBULSKY SUSAN Officer SELL $23.00 5,000 $115,000 401,288
2026-07-20 22:08 2026-07-16 ARTV Artiva Biotherapeutics, Inc. RA CAPITAL MANAGEMENT, L.P. Director, 10% owner BUY $8.93 160,354 $1,432,122 16,977,927
2026-07-20 21:00 2026-07-17 DNA Ginkgo Bioworks Holdings, Inc. Coen Steven P. Officer OPT+S $7.90 752 $5,943 51,438
2026-07-20 20:16 2026-07-17 BCDA BioCardia, Inc. Altman Peter Director, Officer BUY $0.83 500 $415 368,885
2026-07-20 18:27 2026-07-20 GRML Greenland Mines Ltd McGarity Jon Director BUY $0.18 140,000 $24,822 551,277
2026-07-17 20:15 2026-07-15 CGON CG Oncology, Inc. POST LEONARD E Director OPT+S $71.17 1,000 $71,170 0
2026-07-17 23:23 2026-07-15 ADPT Adaptive Biotechnologies Corp LO FRANCIS Officer OPT+S $22.59 105,762 $2,389,164 230,713
2026-07-17 20:40 2026-07-16 RGEN REPLIGEN CORP Garland Jason K Officer SELL $150.00 530 $79,500 18,829
2026-07-17 20:05 2026-07-16 GLUE Monte Rosa Therapeutics, Inc. Warmuth Markus Director, Officer SELL $23.18 9,500 $220,219 585,038
2026-07-17 15:12 2026-07-16 GRML Greenland Mines Ltd LeBlanc Jeff Officer BUY $0.18 1,400,000 $245,280 4,820,342
2026-07-16 22:08 2026-07-15 GILD GILEAD SCIENCES, INC. Dickinson Andrew D Officer SELL $129.93 3,000 $389,777 168,646
2026-07-16 20:45 2026-07-15 MRNA Moderna, Inc. Hoge Stephen Officer OPT+S $67.60 53,336 $3,605,514 1,483,848
2026-07-16 20:54 2026-07-15 GILD GILEAD SCIENCES, INC. Mercier Johanna Officer SELL $129.92 3,000 $389,758 121,234
SHOW ENTRIES

Sector-Wide Insider Alpha

Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.

SEC Filings in Biological Products, (No Diagnostic Substances)

Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.